Skip to main
ILMN
ILMN logo

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 42 analyst ratings
Buy
Strong Buy 26%
Buy 26%
Hold 36%
Sell 10%
Strong Sell 2%

Bulls say

Illumina has demonstrated an ability to increase revenue even as it reduces the cost of sequencing, attributed to demand elasticity, which suggests that higher sample volumes and deeper sequencing requirements can counterbalance price declines. The company aims to accelerate revenue growth to high single digits by 2027, underpinned by a strong pipeline of multiomic technologies and workflows. Additionally, Illumina maintains robust earnings per share growth projections, anticipating approximately 14% growth in 2026, despite potential headwinds in the Chinese market, indicating solid underlying financial health and future profitability.

Bears say

Illumina has lowered its 2025 guidance for non-GAAP diluted EPS to $4.50, reflecting reduced earnings expectations primarily due to challenges in the Chinese market and ongoing macroeconomic trends. The company faces significant headwinds, including a 40% decline in stock value since Q4'24, largely driven by concerns over potential operational limitations in China and increased competition within the life sciences tools sector. Additionally, the persistent demand weakness in China, which represents about 7% of sales, further complicates Illumina's revenue growth prospects and may result in its valuation continuing to trade at a discount compared to industry peers.

Illumina (ILMN) has been analyzed by 42 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 26% recommend Buy, 36% suggest Holding, 10% advise Selling, and 2% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Buy based on their latest research and market trends.

According to 42 analysts, Illumina (ILMN) has a Buy consensus rating as of Jul 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $176.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $176.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.